US Health Care ETFs

Here’s my analysis of some notable overlooked and out-of-favor ETFs that could rebound in 2026.

Small-cap biotech ETFs focus on early-stage companies, offering explosive upside potential but higher risks compared to market-cap weighted competitors.

This week, Strategas ETF expert Todd Sohn updates his "Market Anxiety Meter" and highlights two key diversifiers for tech-heavy U.S. markets.

Here's a look at which ETFs were hurt or helped the most by the launch of this new AI model.

Here’s a look at which ETFs stand to win or lose from the 47th president’s latest spate of executive orders.

This week, Strategas ETF expert Todd Sohn analyzes the significant surge in ETF flows, highlighting the key differences between the current trend and the last major peak in late 2021.

Here's what you need to know about the three defensive sectors in the S&P 500

Shares of major U.S. health insurers have taken a significant hit as the final 2025 Medicare Advantage plan payment rates fall short of industry expectations, raising concerns about margins.

Here's a look at some of the most interesting prospective ETFs awaiting regulatory review and approval as of March.

Here's an overview of what market valuations look like lately on a sector basis, along with some ETFs you can use to invest in them.